secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001493152-23-027331
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q2 revenue $11.0M (+49% YoY); net income $0.4M vs loss
----------------------------------------------------------------

- Q2 net revenue $11.0M, up 49% YoY; gross margin improved to 62% from 52%.
- Income from continuing operations $0.4M vs loss of $2.1M in Q2 2022.
- Adjusted EBITDA $1.3M vs $(1.6)M loss; cash collections $10.2M, up 23% YoY.
- Test volume up 15% YoY; cash balance increased to $5.1M from $1.9M.
- Company faces Novitas LCD challenge for PancraGEN test; expects resolution in months to year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223027331/0001493152-23-027331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223027331/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer